Skip to content

In the BioHarmony Drug Report Database

Trastuzumab deruxtecan

Enhertu (trastuzumab deruxtecan) is an antibody pharmaceutical. Trastuzumab deruxtecan was first approved as Enhertu on 2019-12-20. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. It is known to target receptor tyrosine-protein kinase erbB-2.
Trade Name Enhertu
Common Name Trastuzumab deruxtecan
Indication breast neoplasms, gastrointestinal neoplasms
Drug Class Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)
Trastuzumab deruxtecan
Get full access now